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GENET ICALLY  ENHANCED 
CARDIOVASCULAR IMPLANTS 
LOCAL RELEASE OF  B IOACTIVE  SUBSTANCES 
FROM METALL IC  STENTS 
Coronary artery stenting with permanent metallic implants is 
arguably the most important advance in interventional cardiology 
since balloon angioplasty. More than 250,000 devices were im- 
planted in the United States during 1995, and the growth of 
stenting is expected to be exponential for the next several years. 
Stenting, however, is associated with three important problems: 
thrombosis, restenosis, and inapplicability to smaller coronary 
vessels. These problems limit extension of stenting to a much 
broader cohort of patients, and problems form the rationale for 
developing new stent echnologies. 
The first problem is that stent hrombosis occurs during the 
first 3 weeks after implantation i  1% to 10% of patients, depending 
on a host of factors that predict hrombotic risk. Stent hrombosis 
is a sudden catastrophic event hat most often presents as acute 
myocardial infarction with a high incidence of death. Newer 
antiplatelet agents and optimal stent deployment techniques are 
making asignificant impact on stent hrombosis; however, the most 
popular antiplatelet therapy with ticlopidine has a 2% incidence of 
agrannlocytosis, and overly aggressive deployment can result in 
acute complications requiring additional stenting or emergency 
bypass urgery. 
Stent hrombosis appears to be mediated by multiple mecha- 
nisms. We have demonstrated in aporcine x-vivo shunt model that 
shear stress caused by high flow velocity in small vessels, inad- 
equately expanded stents, and microshear f om rough stent sur- 
faces activates platelets and promotes platelet-rich t rombosis. The 
extent of vessel injury by the deployed stent also contributes to 
thrombosis. We have shown in rabbit carotid and pig coronary 
models with two stent types that the extent of vessel injury 
measured by the depth of strut penetration a d the extent ofmediai 
smooth muscle cell necrosis directly correlates with the mass of 
fibrin-rich thrombus adherent to stents in the first 4 to 7 days after 
implantation. Systemic and local prothrombotic and fibtinolytic 
factors probably also play an important role. 
The second problem isthat current restenosis rates remain too 
high for more widespread pplication. Coronary stenting isthe only 
device or therapy thus far to reduce the incidence of restenosis. 
Although restenosis rates are significantly lower than those for 
conventional balloon angioplasty in ideal, de novo lesions, resteno- 
sis still occurs in 15% to 20%. Ideal lesions only account for about 
one fourth of current stent cases. The majority of stents are placed 
in more complex lesions, including restenotic lesions, saphenous 
vein grafts, ostial esions, long lesions, and chronic total occlusions. 
In these more complex anatomies, stent restenosis occurs in 35% to 
50% of cases. 
The mechanism ofrestenosis differs in stenting comparcd with 
balloon or atherectomy angioplasty. In the latter cases, unfavorable 
vessel remodeling (vessel shrinkage) predominates in three fourths 
of cases. Neointimal proliferation occurs frequently but accounts 
for only a minor portion of the late loss of luminal dimensions. With 
stenting, the scaffolding support of the implant eliminates recoil 
and unfavorable vessel remodeling after injury. The only mecha- 
nism ofrestenosis with stents is exaggerated neointima formation 
resulting from vascular injury-induced smooth muscle cell migra- 
tion and proliferation. Thus stenting isthe ideal injury to study the 
effects of antiproliferative strategies. 
Lastly, stent placement has been largely confined to vessels with 
a normal reference diameter >2.7 mm. This is because thrombosis 
and restenosis rates are even higher for smaller vessels. This is 
important because approximately 50% of all angioplasties are 
performed in these smaller vessels. 
We believe that a metallic stent hat is capable of delivering a 
variety of substances in high concentration precisely to the site of 
arterial injury may be advantageous fordiscovering and implement- 
ing successful treatment s rategies for thrombosis and restenosis. 
Our fundamental im is to create ahybrid device consisting of an 
optionally removable hitinol coronary stent combined with a 
polymer membrane local pharmacologic delivery system that will 
address the relevant clinical problems of stenting. 
We have developed a practical method of covalently linking 
a molecular monolayer of PEO or pleuronics to a metal or 
polymer membrane surface. This surface modification (200 ng 
PEO/stent) reduces high shear stress (2100s-1)-induced platelet 
adhesion and thrombus accumulation on the stent by 95% versus 
controls in a porcine ex-vivo shunt mode. This modification is
significantly (fivefold to 10-fold) more effective than systemic 
aspirin (10 mg/kg), or heparin (100 U/kg), and is equivalent to 
systemic treatment with the monoclonal ntibody to Gp IIbIIIa 
m7E3 at 8 gg/kg. Six-month canine coronary implants how no 
thrombosis or local inflammatory changes. Nitinol stent sur- 
face modification with PEO appears to be biocompatible and 
appears to effectively prevent stent thrombosis n these animal 
models. 
We have previously shown that stents coated with a polyure- 
thane membrane are capable of loading milligram quantities of 
small lipophilic drugs and delivering them to the arterial wall in 
locally high and sustained concentrations. Weare currently devel- 
oping a modification of this polymer that contains a controllable 
network of hollow cells and interconnecting channels which vary 
from 2 to 10 gm in diameter. This porous membrane is designed to 
permit uptake of significant quantities of hydrophilic molecules, 
including proteins, oligonucleotides, and viral vectors for gene 
therapy. So far, these porous membranes can concentrate model 
large molecules uch as lysozyme at concentrations more than 
100-fold greater than the control, nonporous membranes. The 
polymer-coated stent will be tested for biocompatibility and 
mechanical properties in the rabbit carotid and pig coronary 
models. 
We are currently exploring local drug delivery with three 
candidate substance classes, all of which may affect he genetic 
programming of the local vascular microenvironment at the level of 
the vascular smooth muscle cell. The first candidate agent is 
octreotide, a hydrophilic polypeptide somatostatin a alog. We have 
demonstrated that octreotide inhibits vascular smooth muscle cell 
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proliferation to balloon injury in the rat by blocking the genetic 
message for the production of the growth factor IGF-1. 
The second agent to be tested is a chimeric hammerhead 
ribozyme homologous to an antisense region of the cell cycle 
regulating message cdc-2 ldnase, or proliferating cell nuclear 
antigen (PCNA), or both. We are the first group to show efficacy for 
ribozyme treatment in vivo, We demonstrated that local arterial 
delivery of these ribozymes inthe balloon-injured rat carotid artery 
blocks intimal hyperplasia by more than 60% and that it specifically 
hmcks out the target messages and the proteins. Ribozyme 
treatment has a theoretic advantage over antisense in that it is 
catalytic, thus regenerating itself, and the RNA/DNA chimer is 
resistant to cleavage by lyric enzymes. The third class of agents to be 
tested will be gene therapy using a polylyzine adenovirus vector 
carrying the gene for the tibozyme selected above. 
Before animal model testing, the kinetic of incorporation and 
release of each candidate agent will be characterized in vitro and 
compared with existing kinetic models of slab membrane behavior. 
Next, the tissue kinetics, bioactivity, and toxicity of the stent- 
delivered substance will be explored in the rabbit carotid artery, 
and, in the most promising cases, in the pig coronary arteries. 
Neal L. Eigler, MD 
Cedars Sinai Medical Center 
Los Angeles, Calif. 
MODIF ICAT ION OF  ART IF IC IAL  HEARTS BY 
GENE TRANSFER 
An estimated 4 million people in the United States have congestive 
heart disease. The annual death rate from this condition isapproxi- 
mately 500,000, and the reduction of these numbers i dependent 
on transplant surgery or a mechanical alternative, such as an 
artificial heart. The low number of donor hearts (about 2000 per 
year), coupled with the randomness of their availability, has lead to 
the use of ventricular assist devices as a short-term option to 
maintain patient well-being until a suitable donor heart becomes 
available. Pumps, such as the HeartMate left ventricular assist 
device (LVAD ) have been used with considerable success for as long 
as 18 months in the US. In the United Kingdom the use of the 
LYAD as a permanent alternative to transplantation has been 
adopted in certain health care institutions. Therefore, improve- 
ments in the performance ofthis type of device by enhancing the 
biocompatibility of the material-blood interface becomes an im- 
portant area for investigation. 
One avenue that has been studied for this purpose is the 
seeding of biomateriat surfaces with autologous cells. Intuitively, 
endothelial cells would appear to be the cell of choice for cardio- 
vascular prostheses. However, the seeding of the blood-contacting 
surfaces of a number of different prostheses with autologous 
endothelial cells to improve their biocompatibility has had limited 
success. Factors that contribute to failure include cellular senes- 
cence, poor attachment to biomaterial surfaces, and impaired 
production of the endothelial-derived factors desired for improve- 
ment in biocompatibility. In addition, anumber of prostheses, such 
as cardiac pumping devices, require a large number of cells for the 
initial seeding due to their large surface area. An alternate celi type 
that does not suffer from these disadvantages is smooth muscle. 
The latter can be isolated easily and expanded in cuimre without 
undergoing senescence; they also attach firmly to many biomate- 
rials. However, they exhibit properties that suggest that their use 
would be fraught with problems, because they not oniy have the 
capacity to proliferate uncontrollably but also present athrombo- 
genie surface. If these disadvantages could be overcome, autolo- 
gous smooth muscle cells would be ideal candidates for lining 
devices uch as the LVAD. 
Smooth muscle cell proliferation is controlled invivo by factors 
released by the endothelium, and one of these; endothelium- 
derived relaxing factor (EDRF), also contributes tothe inhibition 
of platelet adherence to the luminal endothelial cells. NO, the 
chemical identiw ofEDRF, synergizes with endothelinm-produced 
prostacyclin (PGI2) to prevent platelet activation. The recent 
advent of genetic engineering technology provides a way to modify 
the behavior of smooth muscle cells in a manner that allows them 
to mimic the endothelium. If smooth muscle ceils could be 
engineered with the capacity to produce NO and prostacyclin i  a 
constitutive manner, they could provide a nonproliferative, non- 
thrombogenic cell layer for coating biomaterial surfaces in contact 
with blood. Extensive studies have been carried with LVADs 
implanted in calves; therefore, the feasibility of using genetically 
engineered smooth muscle cells for the purposes described above 
was investigated using bovine cells. 
Initial studies used cells isolated from calf thoracic aorta; 
however, saphenous vein smooth muscle cells were also tested at 
each stage of the procedures described below to ensure that the 
findings with arterial-derived cells could be reproduced. Cells were 
grown in standard, minimum essential medium containing Earles 
salts and, in addition, 2 mmol/L glutamine, 20 mmol/L TES- 
NaOH, pH 7.3, 20 mmol/L HEPES-NaOH, pH 7.3, 100 
units/nil penicillin, and 100 units/ml streptomycin (MEMTH). 
Cells were transfected with plasmid constructs containing cDNA 
encoding either bovine endothelial NO synthase (NOS III), 
human prostaglandin H synthase (PGHS), rat GTP: cyclohydro- 
lase I (GTP:CH), or bovine endothelial cell growth factor 
(VEGF). Plasmid constructs were prepared by cloning into com- 
mercial Epstein-Barr virus-derived vectors (pREP 9 or pREP4) that 
retained the ability for episomal replication in mammalian host 
cells. Vectors contained sequences that rendered them resistant to 
either neomycin/G418 (pREP 9) or hygromycin (pREP4) , and the 
inserted coding sequences were driven off a Rous Sarcoma viral 
promoter. DNA was introduced into smooth muscle ceils either 
by square wave electroporation (400 volts, for 20/msec repeated 
20 times) or by use of commercial liposome preparations. After 
transfection, cells were placed in selection medium, which con- 
tained the components described for MEMTH plus the antibiotic 
specific for selection. Control ceils subjected to transfection pro- 
cedures in the absence of DNA died within 8 days when cultured 
in selection media. Antibiotic-resistant cells were grown to con- 
fluence and passaged by trypsinization and replating. This pro- 
cedure was repeated until expression levels of the inserted gene 
declined below levels of detection by Western analysis. In addi- 
tion, expression of NOS III was monitored by assay of nitrite 
anion levels in conditioned media, and this procedure was used 
as an indirect assay for the determination f GTP:CH expression. 
Production of 6-keto prostaglandin FI~ was used to assay PGHS 
activity in transfected cells. Bovine smooth muscle cells main- 
tained expression of NOS III for many passages in culture (12 
to 24), as determined by Western blot analysis using a monoclonal 
antibody specific to the endothelial ceil isoform of NOS. How- 
ever, the levels of NO produced were below the level of detection 
using the Greiss procedure for nitrite anion determination. I  the 
prcscnce of sepiapterin, a membrane-permeable, exogenous 
source of tetrahydrobiopterin (BH4), nitrite anion production by 
NOS III-transduced cells ranged from 12.54 + 1.19 to 
18.32 T- 2.11 nmol/106 cells. BH4 is an essential cofactor for the 
production of NO by NOS, and its synthesis i  regulated by the 
enzyme GTP :CH. This enzyme is constitutively active in a 
